603858 步長製藥
按盤價 
17.910 +1.030 (+6.102%) | 2024/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 5,431,672 | -21.93% | 13,245,133 | 14,951,253 | 15,762,680 | 16,006,714 | |
| 減：營業總成本 | 5,064,719 | -19.36% | 12,225,170 | 13,248,890 | 14,146,147 | 13,839,082 | |
| 其中:營業成本 | 2,335,236 | 7.18% | 4,218,282 | 4,232,510 | 4,132,796 | 3,741,011 | |
| 財務費用 | 59,378 | 63.23% | 91,663 | 113,527 | 140,678 | 118,143 | |
| 資產減值損失 | (22,291) | 135.70% | (700,722) | (3,035,204) | (138,650) | 2,259 | |
| 公允價值變動收益 | (2,953) | -350.70% | (2,356) | -- | (60,000) | -- | |
| 投資收益 | 3,224 | -83.36% | 21,293 | 2,735 | 17,614 | 15,618 | |
| 其中：對聯營企業和合營企業的投資收益 | 5,034 | -38.40% | 10,301 | (1,115) | 12,601 | 12,289 | |
| 營業利潤 | 409,579 | -53.32% | 436,019 | (1,249,459) | 1,620,574 | 2,365,365 | |
| 利潤總額 | 403,973 | -53.26% | 394,557 | (1,259,389) | 1,586,569 | 2,360,693 | |
| 減：所得稅費用 | 222,838 | 23.32% | 242,692 | 331,594 | 478,288 | 517,551 | |
| 淨利潤 | 181,135 | -73.50% | 151,865 | (1,590,983) | 1,108,281 | 1,843,142 | |
| 減：非控股權益 | (50,281) | -19.62% | (167,108) | (61,239) | (53,837) | (17,752) | |
| 股東淨利潤 | 231,417 | -68.98% | 318,973 | (1,529,744) | 1,162,118 | 1,860,894 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.211 | -68.72% | 0.288 | -1.383 | 1.051 | 1.683 | |
| 每股派息 (元) * | -- | -- | 0.126 | 0.960 | 0.360 | 0.526 | |
| 每股淨資產 (元) * | 10.206 | -6.29% | 10.503 | 11.177 | 12.524 | 12.014 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 30/09/2024 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
